
Mitogen‐activated protein kinase activity drives cell trajectories in colorectal cancer
Author(s) -
Uhlitz Florian,
Bischoff Philip,
Peidli Stefan,
Sieber Anja,
Trinks Alexandra,
Lüthen Mareen,
Obermayer Benedikt,
Blanc Eric,
Ruchiy Yana,
Sell Thomas,
Mamlouk Soulafa,
Arsie Roberto,
Wei TzuTing,
KlotzNoack Kathleen,
Schwarz Roland F,
Sawitzki Birgit,
Kamphues Carsten,
Beule Dieter,
Landthaler Markus,
Sers Christine,
Horst David,
Blüthgen Nils,
Morkel Markus
Publication year - 2021
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.15252/emmm.202114123
Subject(s) - wnt signaling pathway , colorectal cancer , kras , biology , cancer research , transcriptome , organoid , cancer , protein kinase a , cancer cell , cell growth , kinase , microbiology and biotechnology , signal transduction , gene , genetics , gene expression
In colorectal cancer, oncogenic mutations transform a hierarchically organized and homeostatic epithelium into invasive cancer tissue lacking visible organization. We sought to define transcriptional states of colorectal cancer cells and signals controlling their development by performing single‐cell transcriptome analysis of tumors and matched non‐cancerous tissues of twelve colorectal cancer patients. We defined patient‐overarching colorectal cancer cell clusters characterized by differential activities of oncogenic signaling pathways such as mitogen‐activated protein kinase and oncogenic traits such as replication stress. RNA metabolic labeling and assessment of RNA velocity in patient‐derived organoids revealed developmental trajectories of colorectal cancer cells organized along a mitogen‐activated protein kinase activity gradient. This was in contrast to normal colon organoid cells developing along graded Wnt activity. Experimental targeting of EGFR‐BRAF‐MEK in cancer organoids affected signaling and gene expression contingent on predictive KRAS/BRAF mutations and induced cell plasticity overriding default developmental trajectories. Our results highlight directional cancer cell development as a driver of non‐genetic cancer cell heterogeneity and re‐routing of trajectories as a response to targeted therapy.